Biblio Discovery — Demo Discovery Service

5 results for "Matthew Labriola"

Showing 1–5 · 0.26 seconds · RSS

  1. Journal Article

    Pragmatic trials in renal cell carcinoma

    Zachary Creech; Daniel J. George; Matthew Labriola

    Kidney Cancer, Vol. 9 · 2025 · English · DOAJ Scopus

    Therapeutic options for Renal Cell Carcinoma (RCC) are rapidly advancing. Systemic immune-oncology (IO) treatments, including immune checkpoint inhibitor (ICI) combination therapy and ICI with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF TKIs), have shown substantial overall…

  2. Journal Article

    Duke Cancer Care Experience: a longitudinal, multidisciplinary oncology curriculum for medical students

    Anagh Kulkarni; Zachary Creech; Khalid Tejan-Sie et al.

    BMC Medical Education, Vol. 26 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Background Cancer prevalence continues to rise in the United States with a projected shortage of oncologists in the workforce. Despite this need, medical schools often lack oncology-focused education in their curriculum. Duke’s Cancer Care Experience (CCE) is a multi-disciplinary elective…

  3. Journal Article

    Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients

    Tian Zhang; Sarabjot Pabla; Felicia L. Lenzo et al.

    OncoImmunology, Vol. 9 No. 1 · 2020 · English · DOAJ Scopus

    Background Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for immune checkpoint inhibitors (ICIs) in mRCC, but has shown minimal clinical utility and is not used in routine clinical practice…

  4. Journal Article

    Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

    Jeffrey M. Conroy; Sarabjot Pabla; Mary K. Nesline et al.

    Journal for ImmunoTherapy of Cancer, Vol. 7 No. 1 · 2019 · English · DOAJ Scopus

    Abstract Background PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with a different ICI. We set to test if next…

  5. Journal Article

    Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients

    Sarabjot Pabla; Jeffrey M. Conroy; Mary K. Nesline et al.

    Journal for ImmunoTherapy of Cancer, Vol. 7 No. 1 · 2019 · English · DOAJ Scopus

    Abstract Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other factors influence sensitivity to ICIs in…